Compass Therapeutics, Inc. — Director's Dealing 2020

Jun 24, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (NONE)
CIK: 0001738021
Period of Report: 2020-06-17

Reporting Person: Bisker-Leib Vered (Chief Operating Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	513401	Direct

Footnotes

F1: 410,530 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on February 22, 2018, 2,618.3125 shares vest per month with shares fully vested on February 28, 2022, restricted stock award granted on February 22, 2018, shares fully vest upon the satisfaction of performance conditions, restricted stock award granted on July 3, 2019, 2,693.9792 shares vest per month with shares fully vested on July 31, 2023, and restricted stock award granted on December 20, 2019, 25% cliff on December 20, 2020; 4,074.417 shares vest per month thereafter with shares fully vested on December 31, 2023.